Antiviral heterocyclic compounds

A compound represented by Formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• A is selected from the group consisting of:
• 1) optionally substituted aryl;
• and
• 2) optionally substituted heteroaryl;
• B is O;
• R1 and R2 are each hydrogen;
• Z is hydrogen;
• W is
• optionally substituted —C1-C6 alkyl;
• G is
• —C(O)NR11R12;
• n is 1;
• Y is O;
• E is optionally substituted aryl;
• R3 is hydroxy or fluorine;
• R4 is selected from the group consisting of
• optionally substituted —C1-C6 alkyl and
• optionally substituted —C3-C8 cycloalkyl;
• R11 at each occurrence is independently selected from the group consisting of:
• 1) hydrogen;
• 2) optionally substituted —C1-C8-alkyl;
• 3) optionally substituted —C3-C8-cycloalkyl;
• 4) optionally substituted 3- to 8-membered heterocyclic;
• 5) optionally substituted aryl;
• 6) optionally substituted arylalkyl;
• 7) optionally substituted heteroaryl;
• and
• 8) optionally substituted heteroarylalkyl;
• and
• R12 at each occurrence is independently selected from the group consisting of:
• 1) hydrogen;
• 2) optionally substituted —C1-C8-alkyl;
• 3) optionally substituted —C3-C8-cycloalkyl;
• 4) optionally substituted 3- to 8-membered heterocyclic;
• 5) optionally substituted aryl;
• 6) optionally substituted arylalkyl;
• 7) optionally substituted heteroaryl;
• and
• 8) optionally substituted heteroarylalkyl;
• alternatively, R11 and R12 are taken together with the nitrogen atom to which they are attached to form a 3- to 12-membered heterocyclic ring.